Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Methylene Blue in Septic Shock
NCT07264543Phase 3Recruiting
- Sponsor
- CEPETI
- Start
- Jan 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylene blue in septic shock (2 arms), sponsored by CEPETI. Primary endpoint: Feasibility of the study protocol at 28 days. Started Jan 2026; status: recruiting.
02
Drugs
methylene blue
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT07264543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264543.